Hoda Tawfik

Hoda Tawfik

Company: InflaRx N.V.

Job title: Immunoderm Program Director


Vilobelimab, a First-In-Class Anti-C5a Antibody for the Treatment of the Neutrophil Driven Skin Diseases Hidradenitis Suppurativa & Pyoderma Gangraenosum 2:50 pm

Revisiting the role of C5a in neutrophil driven skin diseases Connecting the dots – vilobelimab development for neutrophil driven skin diseases A view on endpoints for HS – whatmatters for patients?Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.